QUINTESSENTIAL-2

A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Exposed Multiple Myeloma

Near Add Your Location

Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
  • Show Principal Investigator
Ochsner LSU Health Shreveport
Ochsner Louisiana State University
Shreveport, LA
  • Accepting patients
Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients
Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
  • Accepting patients
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.